Navigation Links
Pharmos Corporation Reports 2008 First Quarter Results
Date:5/8/2008

he Company's NanoEmulsion delivery technology, formulated with 3% diclofenac cream, to treat osteoarthritis of the knee commenced in June 2007 targeting 126 patients. Completion of patient recruitment is expected in mid 2008.

General and administrative expenses for the first quarter of 2008 decreased by $1,663,772, or 68%, from $2,460,696 in 2007 to $796,924 in 2008. The decline reflects decreases in virtually every general and administrative expense category. The primary reductions include a $792,730 reduction in payroll and a $674,286 reduction in consultant and professional fees. The decrease in payroll costs reflect the impact of the third and fourth quarter 2007 restructuring plans which have reduced the Company's head count from 51 employees in March 2007 to 14 employees in March 2008. The decrease in consulting and professional fees in 2008 result from non recurring 2007 costs related to contractual payment obligations associated with the retirement of the Company's chief executive officer, higher legal and accounting fees in 2007 and a non recurring recruitment fee of $42,000 in 2007.

Net Operating Loss Shareholder Notice

Under Internal Revenue Code Section 382 rules, a change in ownership can occur whenever there is a shift in ownership by more than 50 percentage points by one or more five-percent shareholders within a three-year period. When a change of ownership is triggered, the Company's net operating losses (NOL) asset may be impaired. The Company believes that substantially all of its Federal NOL generated since 1995 are not impaired, and requests that all investors contact the Company prior to allowing their ownership interest to reach a five-percent level.

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoim
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
5. Pharmos Corporation Announces Board and Management Changes
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. BioElectronics Corporation Announces Singapore and Malaysia Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... interface is the device," Nobel laureate Herbert Kroemer ... be found at the junctures where layers of ... nanotechnology, the interfaces between layers of metal oxides ... high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics and ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... A study has been launched to test ... track could help to tackle the problem of obesity.  This ... GP surgery based in Stowmarket) and academics at University Campus ... Telemetry technology, which is inspired by equipment used to collect ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... May 14 Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ... first,quarter ended March 31, 2008., "We had ... with,our collaborations and refocusing our operations to advance ... Chief Executive Officer.,"Roche,s recent decision to license R3487/MEM ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that ... from the U.K. Medicines and Healthcare,products Regulatory ... (CTA),to begin a Phase II clinical trial ... paclitaxel and carboplatin in patients with,advanced head ...
... China Sky One,Medical, Inc. (OTC Bulletin Board: CSKI; ... marketer and distributor of pharmaceutical,medicinal and diagnostic products, ... were made in conjunction with the Company,filing an ... Stock Exchange., As of May 7, 2008, ...
Cached Biology Technology:Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 2Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 3Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 4Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 5Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 6Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 7Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2China Sky One Medical, Inc. Changes Management Team 2China Sky One Medical, Inc. Changes Management Team 3
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
(Date:4/17/2014)... Current Biology on April 17 have discovered ... Brazilian insects, which represent four distinct but related species ... example of an animal with sex-reversed genitalia. , ... animals, Neotrogla is the only example in ... Yoshizawa from Hokkaido University in Japan. , During copulation, ...
(Date:4/17/2014)... at the University of Texas Medical Branch at ... women treated with radiation for cervical cancer should ... , The UTMB researchers, finding a high ... survivors treated with radiation, offer new recommendations that ... cancer screening about eight years after their initial ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2
... People with high cholesterol in their early 40s are ... low cholesterol, according to research that will be presented ... Annual Meeting in Chicago, April 1219, 2008. "Our ... and patients to attack high cholesterol levels in their,40s ...
... antioxidants as a way to improve health by filling ... studies found no evidence that the nutrition supplements extend ... could increase risk for death. The reviewers want ... researcher with the U.S. Department of Agriculture said that ...
... Fla. University of Florida researchers have identified a gene ... the physical effects of mental stress to the point ... Searching for the presence of this gene may be one ... risk for the phenomenon, said David S. Sheps, M.D., a ...
Cached Biology News:Antioxidant users don't live longer, analysis of studies concludes 2Antioxidant users don't live longer, analysis of studies concludes 3Mental stress reduces blood flow to the heart in patients with gene variation 2Mental stress reduces blood flow to the heart in patients with gene variation 3
Naked1 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Leucine-rich repeat-containing G-protein coupled receptor 4...
Biology Products: